Connecting via Winsock to STN

STN STRUCTURE SEARCH (REGISTRY/CAPLUS)

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:38:10 ON 12 SEP 2008

=> FIL REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:38:41 ON 12 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 SEP 2008  HIGHEST RN 1048736-36-2
DICTIONARY FILE UPDATES:  11 SEP 2008  HIGHEST RN 1048736-36-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10579675\1.str
```





chain nodes :
7 8 14 16 17 19
ring nodes :
1 2 3 4 5 6 9 10 11 12 13
chain bonds :
5-7 7-8 8-9 8-16 12-17 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
8-9 8-16 9-10 9-13 10-11 11-12 12-13 12-17 13-14
exact bonds :
5-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 16:CLASS 17:CLASS 19:CLASS 20:Atom

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 13:38:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1971 TO ITERATE

100.0% PROCESSED 1971 ITERATIONS 43 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 36757 TO 42083
PROJECTED ANSWERS: 467 TO 1253

L2 43 SEA SSS SAM L1

=> D SCAN

L2 43 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzamide, 2-[[[(3R)-2,6-dioxo-3-piperidinyl]amino]methyl]-, hydrobromide (1:1)
MF C13 H15 N3 O3 . Br H

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 43 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Naphthalenecarboxamide, N-(hexahydro-2-oxo-1H-azepin-3-yl)-N-[[4-(phenylmethoxy)phenyl]methyl]-
MF C31 H30 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> S L1 FULL
FULL SEARCH INITIATED 13:39:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    39542 TO ITERATE

100.0% PROCESSED    39542 ITERATIONS                          782 ANSWERS
SEARCH TIME: 00.00.02

L3          782 SEA SSS FUL L1
```

```
=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               178.82     179.03

FILE 'CAPLUS' ENTERED AT 13:39:43 ON 12 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 12 Sep 2008  VOL 149 ISS 12
FILE LAST UPDATED: 11 Sep 2008  (20080911/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html
```

```
=> S L3
L4          30 L3

=> D IBIB 1-5
```

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:492994 CAPLUS
DOCUMENT NUMBER: 148:449472
TITLE: Preparation of glutarimides and their use as inhibitors of interleukin Il-12 production
INVENTOR(S): Germann, Tieno; Frosch, Stefanie; Wade, Erik; Buschmann, Helmut; Zimmer, Oswald
PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
SOURCE: U.S. Pat. Appl. Publ., 14pp., Cont.-in-part of Appl. No. PCT/EP2001/00155.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030064987	A1	20030403	US 2002-198073	20020719
US 6656937	B2	20031202		
DE 10002509	A1	20010726	DE 2000-10002509	20000121
WO 2001053261	A1	20010726	WO 2001-EP155	20010109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20040048859	A1	20040311	US 2003-653188	20030903

PRIORITY APPLN. INFO.: DE 2000-10002509 A 20000121
WO 2001-EP155 A2 20010109
US 2002-198073 A3 20020719

OTHER SOURCE(S): CASREACT 148:449472; MARPAT 148:449472

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:100650 CAPLUS
DOCUMENT NUMBER: 148:396412
TITLE: Identification of γ-Secretase Inhibitor Potency Determinants on Presenilin
AUTHOR(S): Zhao, Byron; Yu, Mei; Neitzel, Martin; Marugg, Jennifer; Jagodzinski, Jacek; Lee, Mike; Hu, Kang; Schenk, Dale; Yednock, Ted; Basi, Guriqbal
CORPORATE SOURCE: Elan Pharmaceuticals Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of Biological Chemistry (2008), 283(5), 2927-2938
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207561 CAPLUS
DOCUMENT NUMBER: 147:502250
TITLE: Preparation of N-heterocyclic acetamides useful for viral inhibition
INVENTOR(S): Barsanti, Paul; Brammier, Nathan; Chang, Bryan; Ni, Zhi-Jie; Wang, Weibo; Weiner, Amy
PATENT ASSIGNEE(S): Novartis AG, USA
SOURCE: PCT Int. Appl., 91pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120160	A2	20071025	WO 2006-US23555	20060616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006342209	A1	20071025	AU 2006-342209	20060616
CA 2612490	A1	20071025	CA 2006-2612490	20060616
EP 1901752	A2	20080326	EP 2006-850498	20060616
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
MX 200716064	A	20080310	MX 2007-16064	20071214
IN 2007DN09774	A	20080620	IN 2007-DN9774	20071217
KR 2008031281	A	20080408	KR 2008-701111	20080115

PRIORITY APPLN. INFO.: US 2005-692007P P 20050616
WO 2006-US23555 W 20060616

OTHER SOURCE(S): MARPAT 147:502250

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1101551 CAPLUS
DOCUMENT NUMBER: 147:514375
TITLE: Amino-caprolactam derivatives as γ-secretase inhibitors
AUTHOR(S): Parker, Michael F.; Bronson, Joanne J.; Barten, Donna M.; Corsa, Jason A.; Du, Wengsheng; Felsenstein, Kevin M.; Guss, Valerie L.; Izzarelli, Darcy; Loo, Alice; McElhone, Kate E.; Marcin, Larry R.; Padmanabha, Ramesh; Pak, Roger; Polson, Craig T.; Toyn, Jeremy H.; Varma, Sam; Wang, Jian; Wong, Victoria; Zheng, Ming; Roberts, Susan B.
CORPORATE SOURCE: Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(21), 5790-5795
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:514375
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:618951 CAPLUS
DOCUMENT NUMBER: 147:52911
TITLE: Preparation of pyrrolidinones and pyrrolidinethiones substituted in the 3-position with fused heterocycles as interleukin 12 production inhibitors and interleukin 10 production stimulators
INVENTOR(S): Frormann, Sven; Frosch, Stefanie; Griebel, Carsten; Saunders, Derek; Theil, Fritz; Graubaum, Heinz
PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 115pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062817	A1	20070607	WO 2006-EP11440	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102005057912	A1	20070719	DE 2005-102005057912	20051202
EP 1957481	A1	20080820	EP 2006-818896	20061129
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: DE 2005-102005057912A 20051202
WO 2006-EP11440 W 20061129

OTHER SOURCE(S): MARPAT 147:52911
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
Uploading C:\Program Files\STNEXP\Queries\10579675\2.str





chain nodes :
7 8 14 16 17 19
ring nodes :
1 2 3 4 5 6 9 10 11 12 13
chain bonds :
5-7 7-8 8-9 8-16 12-17 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
8-9 8-16 9-10 9-13 10-11 11-12 12-13 12-17 13-14
exact bonds :
5-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 16:CLASS 17:CLASS 19:CLASS 20:Atom

L5 STRUCTURE UPLOADED

=> FIL REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.49	186.52

FILE 'REGISTRY' ENTERED AT 13:41:35 ON 12 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2008 HIGHEST RN 1048736-36-2
DICTIONARY FILE UPDATES: 11 SEP 2008 HIGHEST RN 1048736-36-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> D L5
L5 HAS NO ANSWERS
L5 STR



PHENYL IS ISOLATED

G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> S L5 FULL SUB=L3
FULL SUBSET SEARCH INITIATED 13:42:00 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      782 TO ITERATE

100.0% PROCESSED      782 ITERATIONS                              613 ANSWERS
SEARCH TIME: 00.00.01

L6          613 SEA SUB=L3 SSS FUL L5
```

```
=> FIL CAPLUS
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  42.56     229.08

FILE 'CAPLUS' ENTERED AT 13:42:06 ON 12 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 12 Sep 2008  VOL 149 ISS 12
FILE LAST UPDATED: 11 Sep 2008  (20080911/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html
```

```
=> S L6
L7          17 L6

=> D IBIB 1
```

L7 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:100650 CAPLUS
DOCUMENT NUMBER: 148:396412
TITLE: Identification of γ-Secretase Inhibitor Potency Determinants on Presenilin
AUTHOR(S): Zhao, Byron; Yu, Mei; Neitzel, Martin; Marugg, Jennifer; Jagodzinski, Jacek; Lee, Mike; Hu, Kang; Schenk, Dale; Yednock, Ted; Basi, Guriqbal
CORPORATE SOURCE: Elan Pharmaceuticals Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of Biological Chemistry (2008), 283(5), 2927-2938
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207561 CAPLUS
DOCUMENT NUMBER: 147:502250
TITLE: Preparation of N-heterocyclic acetamides useful for viral inhibition
INVENTOR(S): Barsanti, Paul; Brammier, Nathan; Chang, Bryan; Ni, Zhi-Jie; Wang, Weibo; Weiner, Amy
PATENT ASSIGNEE(S): Novartis AG, USA
SOURCE: PCT Int. Appl., 91pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120160	A2	20071025	WO 2006-US23555	20060616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006342209	A1	20071025	AU 2006-342209	20060616
CA 2612490	A1	20071025	CA 2006-2612490	20060616
EP 1901752	A2	20080326	EP 2006-850428	20060616
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
MX 200716064	A	20080310	MX 2007-16064	20071214
IN 2007DN09774	A	20080620	IN 2007-DN9774	20071217
KR 2008031281	A	20080408	KR 2008-701111	20080115
PRIORITY APPLN. INFO.:			US 2005-692007P	P 20050616
			WO 2006-US23555	W 20060616

OTHER SOURCE(S): MARPAT 147:502250

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1101551 CAPLUS
DOCUMENT NUMBER: 147:514375
TITLE: Amino-caprolactam derivatives as γ-secretase inhibitors
AUTHOR(S): Parker, Michael F.; Bronson, Joanne J.; Barten, Donna M.; Corsa, Jason A.; Du, Wengsheng; Felsenstein, Kevin M.; Guss, Valerie L.; Izzarelli, Darcy; Loo, Alice; McElhone, Kate E.; Marcin, Larry R.; Padmanabha, Ramesh; Pak, Roger; Polson, Craig T.; Toyn, Jeremy H.; Varma, Sam; Wang, Jian; Wong, Victoria; Zheng, Ming; Roberts, Susan B.
CORPORATE SOURCE: Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(21), 5790-5795
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:514375
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1238885 CAPLUS
DOCUMENT NUMBER: 147:211253
TITLE: Balancing focused combinatorial libraries based on multiple GPCR ligands
AUTHOR(S): Koltanshahi, Farhad; Mansley, Tamsin E.; Choi, Sun; Clark, Robert D.
CORPORATE SOURCE: Informatics Research Center, Tripos, Inc., St Louis, MO, 63144, USA
SOURCE: Journal of Computer-Aided Molecular Design (2006), 20(7-8), 529-538
CODEN: JCAMEQ; ISSN: 0920-654X
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:53048 CAPLUS
DOCUMENT NUMBER: 144:128869
TITLE: Preparation of N-(2-oxoazepan-3-yl)sulfonamides as γ-secretase inhibitors for treating Alzheimer's disease and cancers
INVENTOR(S): Galley, Guido; Kitas, Eric, Argirios; Jakob-Roetne, Roland
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005486	A1	20060119	WO 2005-EP7268	20050706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005261932	A1	20060119	AU 2005-261932	20050706
CA 2573372	A1	20060119	CA 2005-2573372	20050706
EP 1768960	A1	20070404	EP 2005-754125	20050706
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101035765	A	20070912	CN 2005-80023701	20050706
JP 2008505948	T	20080228	JP 2007-520712	20050706
BR 2005013379	A	20080506	BR 2005-13379	20050706
US 20060014945	A1	20060119	US 2005-179703	20050712
US 7253158	B2	20070807		
IN 2007CN00123	A	20070824	IN 2007-CN123	20070111
MX 200700468	A	20070308	MX 2007-468	20070112

PRIORITY APPLN. INFO.: EP 2004-103339 A 20040713
WO 2005-EP7268 W 20050706

OTHER SOURCE(S): MARPAT 144:128869
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:53048 CAPLUS
DOCUMENT NUMBER: 144:128869
TITLE: Preparation of N-(2-oxoazepan-3-yl)sulfonamides as γ-secretase inhibitors for treating Alzheimer's disease and cancers
INVENTOR(S): Galley, Guido; Kitas, Eric, Argirios; Jakob-Roetne, Roland
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005486	A1	20060119	WO 2005-EP7268	20050706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005261932	A1	20060119	AU 2005-261932	20050706
CA 2573372	A1	20060119	CA 2005-2573372	20050706
EP 1768960	A1	20070404	EP 2005-754795	20050706
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101035765	A	20070912	CN 2005-80023701	20050706
JP 2008505948	T	20080228	JP 2007-520712	20050706
BR 2005013379	A	20080506	BR 2005-13379	20050706
US 20060014945	A1	20060119	US 2005-179703	20050712
US 7253158	B2	20070807		
IN 2007CN00123	A	20070824	IN 2007-CN123	20070111
MX 200700468	A	20070308	MX 2007-468	20070112
PRIORITY APPLN. INFO.:			EP 2004-103339 A	20040713
			WO 2005-EP7268 W	20050706

OTHER SOURCE(S): MARPAT 144:128869
GI

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [R1 = (un)substituted hetero/aryl; R2-R4, R2'-R4' = H, lower alkyl, Ph or lower alkyl substituted by halogen; R5 = cycloalkyl, (un)substituted hetero/aryl; X = CHR; R = H, lower alkyl; and their pharmaceutically suitable acid addition salts, optical pure enantiomers, racemates or diastereomeric] were prepared as γ-secretase inhibitors. Thus, reductive amination of 3-fluoro-p-anisaldehyde with 3-aminoazepan-2-one and reaction with 5-chlorothiophene-2-sulfonyl chloride gave sulfonamide II. Preferred I inhibited γ-secretase with IC50 < 0.3 μM. I are useful in the treatment of Alzheimer's disease or common cancers.

IT 873371-73-4P, 3-[(3-Fluoro-4-methoxybenzyl)amino]azepan-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-(2-oxoazepan-3-yl)sulfonamides as γ-secretase inhibitors for treating Alzheimer's disease and cancers)

RN 873371-73-4 CAPLUS
CN 2H-Azepin-2-one, 3-[[(3-fluoro-4-methoxyphenyl)methyl]amino]hexahydro- (CA INDEX NAME)

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:447060 CAPLUS
DOCUMENT NUMBER: 142:481942
TITLE: Preparation of 3-benzylaminopyrrolidin-2-ones as sodium and/or calcium channel modulators.
INVENTOR(S): Thaler, Florian; Sabido, David Cibele Maria; Maestroni, Sara; Raveglia, Luca Francesco; Salvati, Patricia
PATENT ASSIGNEE(S): Newron Pharmaceuticals S.P.A., Italy
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

INSTANT APPLICATION

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1533298	A1	20050525	EP 2003-26779	20031121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004295048	A1	20050616	AU 2004-295048	20041116
CA 2546653	A1	20050616	CA 2004-2546653	20041116
WO 2005054190	A1	20050616	WO 2004-EP12957	20041116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685103	A1	20060802	EP 2004-819593	20041116
EP 1685103	B1	20080730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1882536	A	20061220	CN 2004-80034063	20041116
BR 2004016816	A	20070306	BR 2004-16816	20041116
JP 2007511564	T	20070510	JP 2006-540284	20041116
AT 402922	T	20080815	AT 2004-819593	20041116
IN 2006DN02725	A	20070810	IN 2006-DN2725	20060516
NO 2006002231	A	20060518	NO 2006-2231	20060518
MX 2006PA05626	A	20060817	MX 2006-PA5626	20060518
US 20070135410	A1	20070614	US 2006-579675	20060706
PRIORITY APPLN. INFO.:			EP 2003-26779 A	20031121
			WO 2004-EP12957 W	20041116

OTHER SOURCE(S): CASREACT 142:481942; MARPAT 142:481942
GI

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Use of title compds. [I; m = 1-3; X = CH2, O, S, NR6; R1 = alkyl, alkenyl,
alkynyl chain, optionally substituted with CF3, (substituted) Ph, PhO, naphthyl; R2, R3 = H, alkyl, halo, CF3, OH, alkoxy; R4-R6 = H, alkyl] for the preparation of a drug having Na or Ca channel modulating activity is claimed (no data). Thus, (S)-3-aminopyrrolidin-2-one (preparation given) was
stirred with NaBH3CN and 3Å mol. sieves in MeOH; 4-(3-fluorobenzyloxy)benzaldehyde in MeOH was added to give after 3 h 74% (S)-3-[4-(3-fluorobenzyloxy)benzylamino]pyrrolidin-2-one.

IT 188174-94-9P, (S)-3-[4-(3-Fluorobenzyloxy)benzylamino]pyrrolidin-2-one 188175-15-7P 852103-66-3P 852103-67-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylaminopyrrolidin-2-ones as sodium and/or calcium
channel modulators)

RN 188174-94-9 CAPLUS

CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 188175-15-7 CAPLUS

CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]methylamino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 188175-17-9 188175-19-1 188175-20-4
188175-21-5, 3-[4-(3-Fluorobenzyloxy)benzylamino]azepan-2-one
188175-24-8 188175-25-9 852103-70-9,
3-(4-Butoxybenzylamino)pyrrolidin-2-one 852103-71-0
852103-72-1 852103-73-2 852103-74-3
852103-75-4 852103-76-5 852103-77-6
852103-78-7 852103-79-8 852103-80-1
852103-81-2 852103-82-3 852103-83-4
852103-84-5 852103-85-6 852103-86-7
852103-87-8 852103-88-9 852103-89-0
852103-90-3 852103-91-4 852103-92-5
852103-93-6 852103-94-7 852103-95-8
852103-96-9 852103-97-0 852103-98-1
852103-99-2 852104-00-8 852104-01-9
852104-02-0 852104-03-1 852104-04-2
852104-05-3 852104-06-4 852104-07-5
852104-08-6 852104-09-7 852104-10-0
852104-11-1 852104-12-2 852104-13-3
852104-14-4 852104-15-5 852104-16-6
852104-17-7 852104-18-8 852104-19-9
852104-20-2 852104-21-3 852104-22-4
852104-23-5 852104-24-6 852104-25-7
852104-26-8 852104-27-9 852104-28-0
852104-29-1 852104-30-4 852104-31-5
852104-32-6 852104-33-7 852104-34-8
852104-35-9 852104-36-0 852104-37-1
852104-38-2 852104-39-3 852104-40-6
852104-41-7 852104-42-8 852104-43-9
852104-44-0 852104-45-1 852104-46-2
852104-47-3, 3-(4-Benzyloxybenzylamino)piperidin-2-one
852104-48-4, 3-(4-Benzyloxybenzylamino)azepan-2-one
852104-49-5, 3-[4-(2-Fluorobenzyloxy)benzylamino]piperidin-2-one
852104-50-8, 3-[4-(2-Fluorobenzyloxy)benzylamino]azepan-2-one
852104-51-9, 3-[4-(2-Chlorobenzyloxy)benzylamino]piperidin-2-one
852104-52-0, 3-[4-(2-Chlorobenzyloxy)benzylamino]azepan-2-one
852104-53-1, 3-[4-(3-Fluorobenzyloxy)benzylamino]piperidin-2-one
852104-54-2, 3-[4-(4-Fluorobenzyloxy)benzylamino]piperidin-2-one
852104-55-3, 3-[4-(4-Fluorobenzyloxy)benzylamino]azepan-2-one
852104-56-4, 3-[4-(2-Chlorobenzylamino)benzylamino]piperidin-2-one
852104-57-5, 3-[4-(2-Chlorobenzylamino)benzylamino]azepan-2-one
852104-58-6, 3-[4-[(2-Chlorobenzyl)-N-

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-66-3 CAPLUS

CN 2-Pyrrolidinone, 3-[[[3,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852103-67-4 CAPLUS

CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3-methylphenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

methylamino]benzylamino]piperidin-2-one 852148-44-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of 3-benzylaminopyrrolidin-2-ones as sodium and/or calcium channel modulators)

RN 188175-17-9 CAPLUS

CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



RN 188175-19-1 CAPLUS

CN 2-Pyrrolidinone, 3-[[[4-[(4-fluorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 188175-20-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-21-5 CAPLUS
CN 2H-Azepin-2-one, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]hexahydro- (CA INDEX NAME)



RN 188175-24-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]methylamino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-25-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 852103-70-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[(4-butoxyphenyl)methyl]amino]- (CA INDEX NAME)



RN 852103-71-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-72-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-73-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-74-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-fluoro-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-75-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-chloro-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-76-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-77-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methoxy-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-78-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methyl-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-79-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-fluoro-4-(phenylmethoxy)phenyl]methyl]amino]- (CA
INDEX NAME)



RN 852103-80-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-81-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-82-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methyl-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-83-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-84-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methoxy-4-(1-naphthalenylmethoxy)phenyl]methyl]ami no]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-85-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methyl-4-(1-naphthalenylmethoxy)phenyl]methyl]amin o]- (CA INDEX NAME)



RN 852103-86-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-5-methoxy-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-87-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethoxy-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-88-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethyl-4-(pentyloxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-89-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-5-methoxy-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-90-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethoxy-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-91-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-92-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[2-chloro-5-methoxy-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-93-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-fluoro-5-methoxy-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-94-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-5-methoxy-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-95-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethoxy-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852103-96-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3,5-dimethyl-4-(1-naphthalenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852103-97-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)



RN 852103-98-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 852104-00-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-methoxyphenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



RN 852104-01-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



RN 852104-02-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
amino]- (CA INDEX NAME)



RN 852103-99-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-chlorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
amino]- (CA INDEX NAME)



RN 852104-03-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-methoxyphenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



RN 852104-04-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-methoxyphenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-05-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-chlorophenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-06-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-methoxyphenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-07-5 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]
amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-08-6 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(2,3-dichlorophenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-09-7 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-10-0 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(3,4-dimethoxyphenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-11-1 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-12-2 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]methyl]amino]-
1-methyl- (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 852104-13-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-fluorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)



RN 852104-14-4 CAPLUS
CN 2-Pyrrolidinone, 1-methyl-3-[[[3-methyl-4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-15-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-16-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]methyl]methylamino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-17-7 CAPLUS
CN 2-Pyrrolidinone, 1-methyl-3-[[[3-methyl-4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-18-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-19-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]-3-methylphenyl]methyl]methylamino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-20-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-bromophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-21-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-bromophenyl)methoxy]-3-methylphenyl]methyl]methylamino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-22-4 CAPLUS
CN 2-Pyrrolidinone,
3-[[[2-chloro-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-23-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-fluorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-24-6 CAPLUS
CN 2-Pyrrolidinone,
3-[[[3-fluoro-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-25-7 CAPLUS
CN 2-Pyrrolidinone,
3-[[[3-bromo-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-26-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-methoxy-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-27-9 CAPLUS
CN 2-Pyrrolidinone, 1-methyl-3-[[[3-methyl-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-28-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-chlorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-29-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-5-methoxy-4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-30-4 CAPLUS
CN 2-Pyrrolidinone,
3-[[[3,5-dimethoxy-4-[[4-(trifluoromethyl)phenyl]methoxy]
phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-31-5 CAPLUS
CN 2-Pyrrolidinone,
3-[[[3,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methoxy]p
henyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-32-6 CAPLUS
CN 2-Pyrrolidinone,
3-[[[2-chloro-4-[(3,4-dichlorophenyl)methoxy]phenyl]methy
l]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-33-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3-
fluorophenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-34-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-35-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3-methoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-36-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-37-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[2-chloro-4-[(3,5-dimethoxyphenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-38-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,5-dimethoxyphenyl)methoxy]-3-fluorophenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-39-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-[(3,5-dimethoxyphenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-40-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,5-dimethoxyphenyl)methoxy]-3-methoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-41-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,5-dimethoxyphenyl)methoxy]-3-methylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-42-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3,5-dimethoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-43-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,4-dichlorophenyl)methoxy]-3,5-dimethylphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 852104-44-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-[(3,5-dichlorophenyl)methoxy]-5-methoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-45-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[3-bromo-4-[(3,5-dimethoxyphenyl)methoxy]-5-methoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-46-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3,5-dimethoxyphenyl)methoxy]-3,5-dimethoxyphenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 852104-47-3 CAPLUS
CN 2-Piperidinone, 3-[[[4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)



RN 852104-48-4 CAPLUS
CN 2H-Azepin-2-one, hexahydro-3-[[[4-(phenylmethoxy)phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-49-5 CAPLUS
CN 2-Piperidinone, 3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]- (CA
INDEX NAME)



RN 852104-50-8 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]hexah
ydro- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-51-9 CAPLUS
CN 2-Piperidinone, 3-[[[4-[(2-chlorophenyl)methoxy]phenyl]methyl]amino]- (CA
INDEX NAME)



RN 852104-52-0 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[(2-chlorophenyl)methoxy]phenyl]methyl]amino]hexah
ydro- (CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-53-1 CAPLUS
CN 2-Piperidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-
(CA
INDEX NAME)



RN 852104-54-2 CAPLUS
CN 2-Piperidinone, 3-[[[4-[(4-fluorophenyl)methoxy]phenyl]methyl]amino]-
(CA
INDEX NAME)



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852104-57-5 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[[(2-chlorophenyl)methyl]amino]phenyl]methyl]amino
]hexahydro- (CA INDEX NAME)



RN 852104-58-6 CAPLUS
CN 2-Piperidinone,
3-[[[4-[[(2-chlorophenyl)methyl]methylamino]phenyl]methyl]
amino]- (CA INDEX NAME)



RN 852148-44-8 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[[(2-chlorophenyl)methyl]methylamino]phenyl]methyl

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852104-55-3 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[(4-fluorophenyl)methoxy]phenyl]methyl]amino]hexah
ydro- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 852104-56-4 CAPLUS
CN 2-Piperidinone,
3-[[[4-[[(2-chlorophenyl)methyl]amino]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
]amino]hexahydro- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:1006781 CAPLUS
DOCUMENT NUMBER: 140:23241
TITLE: Anti-inflammatory compositions and methods of use
INVENTOR(S): McMaster, Brian
PATENT ASSIGNEE(S): Chemocentryx, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105857	A1	20031224	WO 2003-US16558	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030236249	A1	20031225	US 2002-171097	20020612
US 6727241	B2	20040427		
CA 2487331	A1	20031224	CA 2003-2487331	20030527
CA 2487331	C	20080812		
AU 2003234642	A1	20031231	AU 2003-234642	20030527
EP 1534293	A1	20050601	EP 2003-729143	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1658881	A	20050824	CN 2003-813413	20030527
JP 2005538060	T	20051215	JP 2004-512760	20030527
US 20070072875	A1	20070329	US 2003-536071	20030530
MX 2004PA12389	A	20050622	MX 2004-PA12389	20041209

PRIORITY APPLN. INFO.: US 2002-171097 A 20020612
WO 2003-US16558 W 20030527

OTHER SOURCE(S): MARPAT 140:23241
AB The present invention is directed to pharmaceutical compns. containing active compds., which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using these pharmaceutical compns. Calcium signaling inhibition by and affinity values for CCR1-MIP-1α binding for a few compds. are provided.
IT 634205-14-4, CCX 469 634205-15-5, CCX 285
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory compds. which inhibit activity of MIP-1α and

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RANTES)
RN 634205-14-4 CAPLUS
CN Benzeneacetamide, N-[(2-fluorophenyl)methyl]-N-(hexahydro-2-oxo-1H-azepin-3-yl)-α-phenyl- (CA INDEX NAME)



RN 634205-15-5 CAPLUS
CN Benzeneacetamide, N-[(2-chlorophenyl)methyl]-N-(hexahydro-2-oxo-1H-azepin-3-yl)-α-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:462563 CAPLUS
DOCUMENT NUMBER: 140:42082
TITLE: Parallel liquid synthesis of N,N'-disubstituted 3-aminoazepin-2-ones as potent and specific farnesyl transferase inhibitors
AUTHOR(S): Le Diguarher, Thierry; Ortuno, Jean-Claude; Dorey, Gilbert; Shanks, David; Guilbaud, Nicolas; Pierre, Alain; Fauchere, Jean-Luc; Hickman, John A.; Tucker, Gordon C.; Casara, Patrick J.
CORPORATE SOURCE: Department of Medicinal Chemistry, Institut de Recherches Servier, Croissy sur Seine, 78290, Fr.
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(14), 3193-3204
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:42082
GI



I

AB A rapid structure-activity study was performed by parallel liquid synthesis on N,N'-disubstitution of 3-aminoazepin-2-one to afford potent and specific farnesyl transferase inhibitors with low nM enzymic and cellular activities. The activities of the selected compds. were validated in vivo, and compds. I (R = 2-Cl, 3-Br) presented significant antitumor activity.
IT 635754-15-3P 635754-17-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(N,N'-disubstituted 3-aminoazepin-2-ones as farnesyl transferase inhibitors)
RN 635754-15-3 CAPLUS
CN Benzonitrile, 4-[[5-[[[(4-cyanophenyl)methyl][(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]amino]methyl]-1H-imidazol-1-yl]methyl]-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 635754-14-2
CMF C33 H32 N6 O

Absolute stereochemistry.

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 635754-17-5 CAPLUS
CN Benzonitrile, 4-[[[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl](1H-imidazol-5-ylmethyl)amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 635754-16-4
CMF C25 H27 N5 O

Absolute stereochemistry.



L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 635754-92-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(N,N'-disubstituted 3-aminoazepin-2-ones as farnesyl transferase inhibitors)
RN 635754-92-6 CAPLUS
CN Benzonitrile, 4-[[[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl][[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Biological study); USES (Uses)
(compns. and methods of treatment of cancer)
RN 330549-40-1 CAPLUS
CN Urea, N-[(4-ethoxyphenyl)methyl]-N-(hexahydro-2-oxo-1H-azepin-3-yl)-N'-phenyl- (CA INDEX NAME)



NOT = R4; CLOSE ART

RN 330550-00-0 CAPLUS
CN Urea, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-(hexahydro-2-oxo-1H-azepin-3-yl)-N'-phenyl- (CA INDEX NAME)



L7 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:202479 CAPLUS
DOCUMENT NUMBER: 138:231712
TITLE: Compositions and methods of treatment of cancer
INVENTOR(S): Bamdad, Cynthia C.
PATENT ASSIGNEE(S): Minerva Biotechnologies Corporation, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020279	A2	20030313	WO 2002-US28576	20020905
WO 2003020279	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459583	A1	20030313	CA 2002-2459583	20020905
AU 2002361258	A1	20030318	AU 2002-361258	20020905
US 20030130293	A1	20030710	US 2002-237150	20020905
EP 1425016	A2	20040609	EP 2002-797864	20020905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005507876	T	20050324	JP 2003-524586	20020905
PRIORITY APPLN. INFO.:			US 2001-317302P	P 20010905
			US 2002-376732P	P 20020501
			WO 2002-US28576	W 20020905

OTHER SOURCE(S): MARPAT 138:231712
AB This invention generally relates to compns. and methods for cancer treatment and, in particular, to compns. able to interact (e.g.,bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compns. for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compns. of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivs., enantiomers or functional equivalent The present compns. can also be packaged in kits in some cases.
IT 330549-40-1 330550-00-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964381 CAPLUS
DOCUMENT NUMBER: 138:39538
TITLE: Sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa
INVENTOR(S): Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry Andreson; King, Nigel Paul; Mason, Andrew McMurtrie; Patel, Vipulkumar Kantibhai; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Weston, Helen Elisabeth; Whitworth, Caroline; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100886	A1	20021219	WO 2002-GB2586	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002311432	A1	20021223	AU 2002-311432	20020606
EP 1395606	A1	20040310	EP 2002-738349	20020606
EP 1395606	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508868	T	20050407	JP 2003-503652	20020606
AT 361315	T	20070515	AT 2002-738349	20020606
EP 1839659	A2	20071003	EP 2006-121123	20020606
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
ES 2284877	T3	20071116	ES 2002-738349	20020606
US 20040152697	A1	20040805	US 2003-479534	20031203
US 7084139	B2	20060801		
US 20060160885	A1	20060720	US 2006-378947	20060317
US 7226929	B2	20070605		
US 20060160886	A1	20060720	US 2006-384094	20060317
US 7282497	B2	20071016		
PRIORITY APPLN. INFO.:			GB 2001-14004	A 20010608
			EP 2002-738349	A3 20020606
			WO 2002-GB2586	W 20020606
			US 2003-479534	A3 20031203

OTHER SOURCE(S): MARPAT 138:39538
GI

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II

AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, Ph, heterocyclyl; R2 = alkyl, CF3; NR3R4 = (un)substituted heterocyclic; R5 = fused bicyclic, (un)substituted Ph, heteroarom., aralkyl, heteroarylalkyl] were prepared for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated (no data). Thus, Z-L-Met-OH was treated with H-L-Ala-OCMe2 and the dipeptide was cyclized with acid ion exchange resin to give tert.-Bu (2S)-2-[(3S)-3-benzyloxycarbonylamino-2-oxopyrrolidin-1-yl]propanoate, which was deblocked and sulfonylated with 6-chloro-2-naphthalenesulfonyl chloride, followed by ester hydrolysis and amidation with morpholine to give the sulfonamide II.

IT 478646-60-5DP, polystyrene-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)

RN 478646-60-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]amino]-1-[(1S)-1-methyl-2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:293645 CAPLUS
DOCUMENT NUMBER: 136:325547
TITLE: Novel aminotriazolone compounds as ligands for neuropeptide Y receptors
INVENTOR(S): Fauchere, Jean-Luc; Ortuno, Jean-Claude; Levens, Nigel; Chamorro, Susana; Boutin, Jean Albert
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030923	A1	20020418	WO 2001-FR3133	20011011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2815346	A1	20020419	FR 2000-13125	20001013
FR 2815346	B1	20040220		
CA 2424802	A1	20020418	CA 2001-2424802	20011011
AU 2002010632	A	20020422	AU 2002-10632	20011011
EP 1324998	A1	20030709	EP 2001-978526	20011011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002408	A2	20031229	HU 2003-2408	20011011
BR 2001014632	A	20040217	BR 2001-14632	20011011
JP 2004515475	T	20040527	JP 2002-534309	20011011
MX 2003PA02956	A	20041213	MX 2003-PA2956	20030403
NO 2003001643	A	20030410	NO 2003-1643	20030410
US 20040029875	A1	20040212	US 2003-399098	20030411

PRIORITY APPLN. INFO.: FR 2000-13125 A 20001013
WO 2001-FR3133 W 20011011

OTHER SOURCE(S): MARPAT 136:325547
GI



I

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Novel aminotriazolones were prepared for use for treating neuropeptide Y-related (NPY) pathologies (no data). Thus, 4-H2NC6H4CO2Et was treated with EtO2CNCS to give 4-EtO2CNHCSC6H4CO2Et which was treated with 3-F3CC6H4NHNH2, followed by ester hydrolysis and amidation with (R)-(+)-α-aminobutyrolactone to give the amide I.

IT 412912-14-2P 412912-20-0P 412912-31-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolylaminobenzamides as NPY antagonists)

RN 412912-14-2 CAPLUS
CN 2H-Azepin-2-one, 3-[[[4-[[2,5-dihydro-1-(3-methylphenyl)-5-oxo-1H-1,2,4-triazol-3-yl]amino]phenyl]methyl]amino]hexahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 412912-13-1
CMF C22 H26 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 412912-20-0 CAPLUS
CN 2H-Azepin-2-one, 3-[[[4-[[1-(3-chlorophenyl)-2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl]amino]phenyl]methyl]amino]hexahydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 412912-19-7
CMF C21 H23 Cl N6 O2

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 412912-31-3 CAPLUS
CN 2H-Azepin-2-one, 3-[[[4-[[2,5-dihydro-5-oxo-1-[3-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]amino]phenyl]methyl]amino]hexahydro- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:122938 CAPLUS
DOCUMENT NUMBER: 136:183619
TITLE: Preparation of diphenyl ether amides, oxamides, and ureas for treatment of arteriosclerosis and hypercholesterolemia.
INVENTOR(S): Haning, Helmut; Pernerstorfer, Josef; Schmidt, Gunter; Woltering, Michael; Bischoff, Hilmar; Voehringer, Verena; Kretschmer, Axel; Faeste, Christiane
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012169	A1	20020214	WO 2001-EP8477	20010723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10038007	A1	20020214	DE 2000-10038007	20000804
AU 2001078502	A	20020218	AU 2001-78502	20010723
CA 2417880	A1	20030131	CA 2001-2417880	20010723
EP 1307426	A1	20030507	EP 2001-956554	20010723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030027862	A1	20030206	US 2001-918741	20010731
US 6555580	B2	20030429		
PRIORITY APPLN. INFO.:			DE 2000-10038007 A	20000804
			WO 2001-EP8477 W	20010723

OTHER SOURCE(S): MARPAT 136:183619
GI

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. [I; R1 = NO2, amino, acetamido, NHCOCOA, NHCH2COA; A = OH, alkoxy; R2, R3 = halo, alkyl, CF3; R4 = ENR6R7, ENR9COR8, NHCOR10, CONR11R12; E = alkylene; R6, R7 = (substituted) alkyl, aryl, cycloalkyl, heterocyclyl; R6R7N = heterocyclyl; R8 = (substituted) alkyl, cycloalkyl, aryl, biphenyl, alkoxy; R9 = (substituted) alkyl optionally interrupted by O, cycloalkyl, alkenyl, Ph, pyridyl; R8R9 = atoms to form a 4-7 membered heterocyclyl; R10 = (substituted) alkyl, cycloalkyl, aryl, 5-6 membered (aromatic), (benzoannellated) heterocyclyl; R11, R12 = H, (substituted) alkyl, cycloalkyl, 5-7 membered heterocyclyl; R11R12N = 5-7 membered (benzoannellated) (substituted) (aromatic) heterocyclyl], were prepared Thus, resin-bound substrate (II) was converted to title compound (III) in several steps using isopropylamine, benzyl chloride, and ethoxalyl chloride. Tested I showed T3 thyroid hormone receptor promoter activity with EC50 = 2.4-55 nM.
IT 398522-81-1P 398523-15-4P 398523-25-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di-Ph ether amides, oxamides, and ureas for treatment of arteriosclerosis and hypercholesterolemia)
RN 398522-81-1 CAPLUS
CN Acetic acid, 2-[[4-[3-[[(hexahydro-2-oxo-1H-azepin-3-yl)propylamino]methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-oxo-, ethyl ester (CA INDEX NAME)

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 398523-15-4 CAPLUS
CN Acetic acid, 2-[[4-[3-[[(hexahydro-2-oxo-1H-azepin-3-yl)(phenylmethyl)amino]methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-oxo-, ethyl ester (CA INDEX NAME)



RN 398523-25-6 CAPLUS
CN Acetic acid, 2-[[4-[3-[[[(3-fluorophenyl)methyl](hexahydro-2-oxo-1H-azepin-3-yl)amino]methyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-oxo-, ethyl ester (CA INDEX NAME)

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:234317 CAPLUS
DOCUMENT NUMBER: 126:225223
ORIGINAL REFERENCE NO.: 126:43554h,43555a
TITLE: Preparation of N-(4-substituted-benzyl)-2-aminolactam derivatives as CNS agents
INVENTOR(S): Pevarello, Paolo; Amici, Raffaella; Varasi, Mario; Maj, Roberto; Salvati, Patricia
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.P.A., Italy; Pevarello, Paolo; Amici, Raffaella; Varasi, Mario; Maj, Roberto; Salvati, Patricia
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

IDS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705111	A1	19970213	WO 1996-EP2962	19960705
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2226886	A1	19970213	CA 1996-2226886	19960705
CA 2226886	C	20070130		
AU 9666116	A	19970226	AU 1996-66116	19960705
EP 842152	A1	19980520	EP 1996-925667	19960705
EP 842152	B1	20010131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, SI, FI				
BR 9609847	A	19990309	BR 1996-9847	19960705
JP 11509848	T	19990831	JP 1997-507148	19960705
JP 3939755	B2	20070704		
AT 199013	T	20010215	AT 1996-925667	19960705
ES 2154830	T3	20010416	ES 1996-925667	19960705
ZA 9605997	A	19970131	ZA 1996-5997	19960715
US 5912242	A	19990615	US 1998-981493	19980108

PRIORITY APPLN. INFO.: GB 1995-15411 A 19950727
WO 1996-EP2962 W 19960705

OTHER SOURCE(S): MARPAT 126:225223
GI

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB The title compds. [I; m = 0-3; n = 0-3; X = O, S, CH2, NH; R, R1 = H, C1-6 alkyl, halo, etc.; R2-R4 = H, (un)substituted C1-6 alkyl, C3-C7 cycloalkyl] and their salts, useful as antiepileptic, anti-Parkinson, neuroprotective, anti-depressant, antispastic and/or hypnotic agents, and in treating and preventing neurodegenerative diseases, were prepared and formulated. Thus, treatment of (S)-3-amino-2-pyrrolidinone.HCl with NaBH3CN in MeOH in the presence of 3A mol. sieves followed by addition of 4-(3-fluorobenzyloxy)benzaldehyde in MeOH, and treatment of the free base with MeSO3H afforded I.MeSO3H which showed MES ED50 of 23.7 mg/kg.

IT 188174-94-9P 188174-95-0P 188174-97-2P
188174-98-3P 188175-00-0P 188175-02-2P
188175-03-3P 188175-05-5P 188175-08-8P
188175-09-9P 188175-11-3P 188175-13-5P
188175-14-6P 188175-15-7P 188175-16-8P
188175-17-9P 188175-18-0P 188175-19-1P
188175-20-4P 188175-21-5P 188175-22-6P
188175-23-7P 188175-24-8P 188175-25-9P
188175-26-0P 188175-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-substituted-benzyl)-2-aminolactam derivs. as CNS agents)

RN 188174-94-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 188174-95-0 CAPLUS

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188174-94-9
CMF C18 H19 F N2 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188174-97-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188174-96-1
CMF C18 H19 Cl N2 O2

Absolute stereochemistry. Rotation (-).

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188174-98-3 CAPLUS
CN 2-Piperidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 188175-00-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-bromophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188174-99-4
CMF C18 H19 Br N2 O2

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188175-03-3 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-chlorophenyl)methoxy]phenyl]methyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 188175-05-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188175-04-4
CMF C18 H19 F N2 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188175-02-2 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188175-01-1
CMF C18 H19 F N2 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188175-08-8 CAPLUS
CN 2H-Azepin-2-one, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]hexahydro-, (S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 188175-07-7
CMF C20 H23 F N2 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 188175-09-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[[(3-fluorophenyl)methyl]amino]phenyl]methyl]amino]-, hydrochloride (1:2), (3S)- (CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 188175-11-3 CAPLUS
CN Benzenesulfonamide, 4-[[[(3S)-2-oxo-3-pyrrolidinyl]amino]methyl]-N-(phenylmethyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 188175-10-2
CMF C18 H21 N3 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 188175-13-5 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-3-methyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 188175-12-4
CMF C19 H21 F N2 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 188175-14-6 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-1-methyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 188175-15-7 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]methylamino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 188175-16-8 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]methylamino]-1-(hydroxymethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-17-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)



RN 188175-18-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-bromophenyl)methoxy]phenyl]methyl]amino]- (CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-19-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(4-fluorophenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 188175-20-4 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]-
(CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-21-5 CAPLUS
CN 2H-Azepin-2-one,
3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]hexah
ydro- (CA INDEX NAME)



RN 188175-22-6 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[[(3-fluorophenyl)methyl]amino]phenyl]methyl]amino
]- (CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-23-7 CAPLUS
CN Benzenesulfonamide, 4-[[(2-oxo-3-pyrrolidinyl)amino]methyl]-N-
(phenylmethyl)- (CA INDEX NAME)



RN 188175-24-8 CAPLUS
CN 2-Pyrrolidinone,
3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]methylamino
]- (CA INDEX NAME)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 188175-25-9 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-1-methyl- (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 188175-26-0 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-chlorophenyl)methoxy]phenyl]methyl]methylamino]- (CA INDEX NAME)



RN 188175-27-1 CAPLUS
CN 2-Pyrrolidinone, 3-[[[4-[(3-bromophenyl)methoxy]phenyl]methyl]methylamino]- (CA INDEX NAME)

L7 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1990:45689 CAPLUS
DOCUMENT NUMBER:	112:45689
ORIGINAL REFERENCE NO.:	112:7711a,7714a
TITLE:	Developer composition containing fluoro resin-coated carrier and quaternary ammonium salt-containing toner
INVENTOR(S):	Suzuki, Chiaki; Takeda, Masayuki; Kumashiro, Koichi; Mochizuki, Masao
PATENT ASSIGNEE(S):	Fuji Xerox Co., Ltd., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 7 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01204073	A	19890816	JP 1988-27429	19880210
PRIORITY APPLN. INFO.:			JP 1988-27429	19880210

GI



I

AB The title composition contains a vinylidene fluoride-based copolymer blend-coated ferrite particle carrier and a toner having a binder resin containing a quaternary ammonium salt charge controller. The composition, preventing photog. fog and staining in electrophotog. or electrog. machines, shows stabilized developing property under changing temperature and moisture. Thus, a mixture of Bu acrylate-styrene copolymer, C black, Viscol 660p, and quaternary lactam ammonium salt I were melt kneaded and pulverized to give a toner, which was mixed with a ferrite coated with a mixture of vinylidene fluoride-trifluoroethylene copolymer, poly(Me methacrylate), and DMF to give the title developer composition

IT 120134-94-3
RL: USES (Uses)
(charge controller, for electrophotog. developer containing vinylidene fluoride-based copolymer blend-coated ferrite carrier)

RN 120134-94-3 CAPLUS
CN Benzenemethanaminium, N-(hexahydro-2-oxo-1H-azepin-3-yl)-4-methoxy-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)

L7 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● Cl⁻

L7 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:505772 CAPLUS
DOCUMENT NUMBER: 111:105772
ORIGINAL REFERENCE NO.: 111:17638h,17639a
TITLE: Developers for electrostatic image development comprising a carrier and a toner containing a caprolactam salt as a charge-controlling agent
INVENTOR(S): Kumashiro, Koichi; Suzuki, Chiaki; Shinoki, Masahito
PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01061761	A	19890308	JP 1987-216410	19870901
PRIORITY APPLN. INFO.:			JP 1987-216410	19870901

OTHER SOURCE(S): MARPAT 111:105772
GI



I

AB A carrier prepared by melting a carrier material mixture containing a resin and a magnetic powder as essential components, spraying, and then cooling is combined with a toner containing, as a charge-controlling agent, a caprolactam salt I [R, R1, R2 = H, (substituted) alkyl, (substituted) aryl, (substituted) aralkyl, (substituted) cycloalkyl; X- = anion] to give a developer for electrostatic image development. The developer exhibits good charging properties, environmental stability, and durability. Thus, a mixture of EPT 1000 (magnetic powder) and hydrogenated bisphenol A-butanediol-fumaric acid polyester was melt-kneaded, sprayed, and then cooled to give a carrier, while a mixture of styrene-2-ethylhexyl acrylate copolymer, Regal 330 (C black), Viscol 660P (polypropylene), and I (R = R1 = R2 = H; X- = Cl-) was kneaded and pulverized to obtain a toner.
IT 120134-94-3
RL: USES (Uses)
(charge controlling agent, for electrostatog. developer toner)
RN 120134-94-3 CAPLUS
CN Benzenemethanaminium, N-(hexahydro-2-oxo-1H-azepin-3-yl)-4-methoxy-N,N-

L7 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
dimethyl-, chloride (1:1) (CA INDEX NAME)



● Cl⁻

L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:182941 CAPLUS
DOCUMENT NUMBER: 110:182941
ORIGINAL REFERENCE NO.: 110:30181a,30184a
TITLE: Developer compositions for electrostatic images containing an ammonium salt charge controlling agent
INVENTOR(S): Suzuki, Chiaki; Matsumura, Yasuo; Aoki, Takayoshi; Nakaoka, Kenji; Matsukuma, Yoshihisa
PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Japan; Toray Industries, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63202760	A	19880822	JP 1987-34404	19870219
JP 2543691	B2	19961016		
PRIORITY APPLN. INFO.:			JP 1987-34404	19870219

OTHER SOURCE(S): MARPAT 110:182941
GI



I

AB Developer composition for electrostatic images contain a compound I [R, R1, R2 = H, (substituted) alkyl, (substituted) aryl, (substituted) aralkyl, (substituted) cycloalkyl; X- = anion] as a charge controlling agent. The compound is white color and useful for making color developers and exhibits good dispersibility in binder, and the obtained developers have good charge distribution. Thus, a mixture of 2-ethylhexyl acrylate-styrene copolymer, Regal 330 (C black), Viscol 660P (polypropylene), and I (R = R1 = R2 = H; X- = Cl-) was kneaded, pulverized, and mixed with a carrier obtained from a magnetic powder and Bu acrylate-styrene copolymer to give an electrostatog. developer which showed stable charging properties and excellent durability.
IT 120134-94-3
RL: USES (Uses)
(charge control agent, for electrophotog. developer)
RN 120134-94-3 CAPLUS
CN Benzenemethanaminium, N-(hexahydro-2-oxo-1H-azepin-3-yl)-4-methoxy-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)

L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L7 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:421486 CAPLUS
DOCUMENT NUMBER: 77:21486
ORIGINAL REFERENCE NO.: 77:3587a,3590a
TITLE: Fiber-forming polyamides containing an additive for improving color intensity, modulus of elasticity, and flat spotting
INVENTOR(S): Ottenheym, Johannes H.; Van Krimpen, Pieter C. A.; Franssen, Pierre J.
PATENT ASSIGNEE(S): Stamicarbon N. V.
SOURCE: U.S., 2 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3651023	A	19720321	US 1968-741897	19680702
PRIORITY APPLN. INFO.:			US 1968-741897 A	19680702

AB Caprolactam (I) containing 0.5-5% N,N'-bis(hexahydro-2-oxo-3-azepinyl)-p-xylylenediamine [35108-78-2], N,N'-bis(hexahydro-2-oxo-3-azepinyl)succinic acid diamide [35074-64-7], a mixture of α-(methyleneamino)-ε-caprolactam [35074-65-8], N,N'-bis(hexahydro-2-oxo-3-azepinyl)methylenediamine [35074-66-9] and 1,3,5-tris(hexahydro-2-oxo-3-azepinyl)-s-triazine [35074-67-0], ε-N-methylenelysine [35074-17-0], α-amino-ε-caprolactam [671-42-1], or lysine [56-87-1] was spun into polyamide fibers with improved color intensity, modulus of elasticity and flat spotting. Thus, I containing 1% lysine 0.15% HOAc, and 14.7% H2O was polymerized at 260.deg./5-6 atmospheric for 3 hr, the pressure was reduced to 1 atmospheric, and heating continued an addnl. 3 hr. The mass was extruded into filaments with 7.5-9 g/denier tensile strength, 15-17% elongation at break, 55-65 modulus of elasticity, and 1.2-1.4mm flat-spot index. A similar fiber not processed with lysine had 8.9 g/denier, 14-15%, 45-55, and 2.0-2.3mm values, resp.

IT 35108-78-2
RL: USES (Uses)
(polyamide fibers modified by, for improved elasticity and resistance to flat spotting)
RN 35108-78-2 CAPLUS
CN 2H-Azepin-2-one, 3,3'-[1,4-phenylenebis(methyleneimino)]bis[hexahydro- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)